OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit


Amelia Wall Warner

Amelia Wall Warner

Gentris Corporation, USA

CEO and President
Gentris Corporation


In 2013, Amelia joined Gentris Corporation as CEO and President and a Director on the Gentris Board of Directors. Gentris is a pioneer in genomic biomarker strategy, testing, operations, ethics, consulting, and global regulation and law. The company is also a global leader in biobanking operations, procedures, policy, consulting, and storage. Amelia also serves as the CAP Biorepository Director for Gentris. Amelia is the Founder and CEO of Global Specimen Solutions, Inc.- an innovative company offering pharmacogenomics operation services and consultancy to the pharmaceutical industry. Global Specimen Solutions, Inc provides expert ability to write pharmacogenomic and biomarker protocols, informed consent, negotiate consents, annotate specimen permissions, manage and clean key files, create blinded data sets, manage biorepository activities, design and plan of pharmacogenomic and biomarker corporate strategy and development design. Amelia has over 15 years experience building and incorporating clinical pharmacogenomic research into comprehensive, cohesive, integrated prospective strategy. Amelia conceptualized and built biorepository programs from the ground up at Children's Hospital of Philadelphia, Schering-Plough, and Merck. Customizing programmatic needs from academic programs to pharmaceutical company needs, Amelia has developed optimized approaches for pharmacogenomics, human specimen research, and biobanking that are compliant, maximize return-on-investment, and yield important understanding of human variation in response to drug therapy. She leads international teams focused on optimizing genetic sample collection, data generation, and data transfer globally and continues to work on international policy for both genetic specimens and human specimen research. She was a PhRMA representative to ICH E16 for Genomic Biomarker Data Submissions and is Past Chair of the Industry Pharmacogenomics Working Group.